Research programme: prodrug therapeutics - V ClinBio/Cellix Bio

Drug Profile

Research programme: prodrug therapeutics - V ClinBio/Cellix Bio

Alternative Names: CLX 103; CLX 106

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellix Bio
  • Developer Cellix Bio; V ClinBio
  • Class Acyclic acids; Aminosalicylic acids; Anti-inflammatories; Antifungals; Antihyperlipidaemics; Eicosanoids; Fatty acids; Irritable bowel syndrome therapies; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Immunosuppressants; Inosine monophosphate dehydrogenase inhibitors; Lipoxygenase-cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Multiple sclerosis; Ulcerative colitis

Most Recent Events

  • 06 Feb 2018 V ClinBio acquires 49.98% Stake in Cellix
  • 06 Feb 2018 Preclinical trials in Multiple sclerosis in USA
  • 06 Feb 2018 Preclinical trials in Ulcerative colitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top